Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

WeightWatchers has appointed Dr. Kim Boyd as chief medical officer and announced a new program focused on helping women ...

Walmart Inc. is giving $500,000 in grants and in-kind donations to Central Texas communities hit over the July Fourth weekend ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

A cargo ship attacked by Yemen’s Houthi rebels sank Monday in the Red Sea, the group said, raising new concerns over safety ...

Novo Nordisk confirmed on Monday it would cease its agreement with U.S. telehealth firm Hims & Hers Health regarding its Wegovy weight-loss drug, prompting a 31% dip in Hims shares during morning ...

Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more weight in a shorter time frame compared to Novo Nordisk's Wegovy. According ...

The compounded versions cost consumers considerably less than the brand-name GLP-1 drugs. Novo Nordisk said it had been working with telehealth companies to help transition patients from the ...

In April, Novo Nordisk began partnering with multiple telehealth companies, including Hims & Hers, to expand access to Wegovy after the shortage ended, CNBC reported. Under FDA regulations, compounded ...